sar100842
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2013 (NCT01651143)
Timeline
2010s
- Jan 1, 2013
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Lysophosphatidic acid receptor Edg-2INHIBITOR
LPAR1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
COC1=CC=C(C=C1OCCC2=CC=CC(C)=C2)C(=O)NC3(CC4=C(C3)C=CC=C4)C(O)=O- Mol. weight
- 445.507 g/mol
Oral
No
Parenteral
No
Topical
No
Sources
- NCATSY76WZ464EY ↗
Also known as
- sar100842
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01651143 | Phase 2 | Jan 1, 2013 | Sanofi |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sanofi | For profit | 1 | 1 | 1 | 2013 |
1 organizations
Page 1 / 1